AnaptysBio, Inc. (ANAB)
NASDAQ
55.20
+0.14 (+0.25%)
Closed
Sep 18, 2026
Day's Range
53.7155.77
52 wk Range
13.1072.36
Financial Statements - ANAB - AnaptysBio, Inc.
Revenue
234.60M▲ 157.0%
Net Income
-13.23M▲ 90.9%Net Margin -5.6%
EBITDA
69.24M▲ 174.7%
Free Cash Flow
19.61M▲ 114.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 234.60M | 91.28M | 17.15M | 10.28M | 63.17M | 75M |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 47.89M | -114.94M | -157.07M | -115.15M | -56.81M | -23.87M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 5.43M | 14K | -7.34M | 12K | 37K | -11K |
| Pre Tax Income | -13.06M | -145.22M | -163.62M | -128.70M | -57.79M | -19.93M |
| Income Tax | 164K | 3K | -4K | 24K | 0 | 0 |
| Net Income | -13.23M | -145.23M | -163.61M | -128.72M | -57.79M | -19.93M |
| EPS Basic | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 |
| EPS Diluted | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 |
| Basic Shares Outstanding | 28.75M | 28.38M | 26.92M | 28.16M | 27.43M | 27.30M |
| Diluted Shares Outstanding | 28.75M | 28.38M | 26.92M | 28.16M | 27.43M | 27.30M |
| Ebit | 66.82M | -95.14M | -145.54M | -107.59M | -56.34M | -19.93M |
| Ebitda | 69.24M | -92.74M | -135.82M | -105.25M | -54.25M | -18.31M |
| Net Income Continuous Operations | -13.23M | -145.23M | -163.61M | -128.72M | -57.79M | -19.93M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
